الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

mylan institutional llc - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 2.5 mg in 0.5 ml - arixtra® is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): arixtra is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. arixtra is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. arixtra is contraindicated in the following conditions: available data from published literature and postmarketing reports have not reported a clear association with fondaparinux sodium and adverse developmental outcomes. fondaparinux sodium plasma concentrations obtained from four women treated with arixtra during pregnancy and their newborn infants demonstrated low placental transfer of fondaparinux sodium (see data). there are risks to the mother associated with untreated venous thromboembolism in pregnancy and a risk of hemorrhage in the mother and fetus associated with use of anticoagulants (see

إسرائيل - الإنجليزية - Ministry of Health

padagis israel agencies ltd, israel - fondaparinux sodium - solution for injection - fondaparinux sodium 5 mg / 1 ml - fondaparinux - fondaparinux - prevention of venous thromboembolic events (vte) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture major knee surgery or hip replacement surgery. prevention of venous thromboembolic events (vte) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications such as patients undergoing abdominal cancer surgery. prevention of venous thromboembolic events (vte) in adults medical patients who are judged to be at high risk for vte and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders and/or acute infectious or inflammatory disease. treatment of unstable angina or non-st segment elevation myocardial infarcton (ua/nstemi) in adults for whom urgent ( < 120 mins) invasive management (pci) is not indicated . treatment of st segment elevation myocardial infarction (stemi) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.

إسرائيل - الإنجليزية - Ministry of Health

padagis israel agencies ltd, israel - fondaparinux sodium - solution for injection - fondaparinux sodium 12.5 mg/ml - fondaparinux - fondaparinux - treatment of adults with acute deep vein thrombosis (dvt) and treatment of acute pulmonary embolism (pe), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - fondaparinux sodium, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - fondaparinux is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery.,fondaparinux is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

physicians total care, inc. - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 5 mg in 0.4 ml - arixtra® is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing hip fracture surgery, including extended prophylaxis; - in patients undergoing hip replacement surgery; - in patients undergoing knee replacement surgery; - in patients undergoing abdominal surgery who are at risk for thromboembolic complications. arixtra is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. arixtra is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. arixtra is contraindicated in the following conditions: - severe renal impairment (creatinine clearance [crcl] <30 ml/min). [see warnings and precautions (5.2) and use in specific populations (8.6).] - active major bleeding. - bacterial endocarditis. - thrombocytopenia associated with a positive in vitro test for anti-platelet antib

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk) ltd - fondaparinux sodium - solution for injection - 5mg/1ml

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk) ltd - fondaparinux sodium - solution for injection - 12.5mg/1ml

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk) ltd - fondaparinux sodium - solution for injection - 12.5mg/1ml

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk) ltd - fondaparinux sodium - solution for injection - 12.5mg/1ml

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - fondaparinux sodium - solution for injection - 12.5mg/1ml